Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Sold by Corient Private Wealth LLC

Corient Private Wealth LLC cut its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 66.2% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,787 shares of the medical equipment provider's stock after selling 5,456 shares during the quarter. Corient Private Wealth LLC's holdings in Lantheus were worth $249,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in LNTH. Wilmington Savings Fund Society FSB purchased a new stake in Lantheus in the 3rd quarter worth $25,000. Kestra Investment Management LLC acquired a new stake in shares of Lantheus in the fourth quarter valued at about $27,000. UMB Bank n.a. increased its stake in shares of Lantheus by 31.5% during the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock worth $50,000 after purchasing an additional 134 shares in the last quarter. World Investment Advisors LLC acquired a new position in shares of Lantheus during the 3rd quarter worth about $60,000. Finally, Parkside Financial Bank & Trust lifted its stake in Lantheus by 49.4% in the 4th quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider's stock valued at $76,000 after buying an additional 280 shares in the last quarter. 99.06% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have commented on LNTH. The Goldman Sachs Group began coverage on Lantheus in a research note on Wednesday, December 18th. They set a "buy" rating and a $143.00 price objective for the company. B. Riley dropped their price target on Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a research report on Friday, March 21st. JMP Securities restated a "market outperform" rating and issued a $112.00 price objective on shares of Lantheus in a report on Tuesday, January 14th. Finally, Truist Financial upped their target price on shares of Lantheus from $120.00 to $127.00 and gave the stock a "buy" rating in a report on Thursday, February 27th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $129.43.

Lantheus Stock Down 6.5 %

NASDAQ:LNTH traded down $6.29 on Friday, hitting $90.92. The stock had a trading volume of 1,158,346 shares, compared to its average volume of 946,182. The company has a fifty day moving average price of $93.31 and a two-hundred day moving average price of $96.12. Lantheus Holdings, Inc. has a 1-year low of $58.46 and a 1-year high of $126.89. The stock has a market cap of $6.23 billion, a price-to-earnings ratio of 15.13 and a beta of 0.38.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The business had revenue of $391.11 million during the quarter, compared to analysts' expectations of $376.61 million. As a group, analysts anticipate that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Insider Buying and Selling at Lantheus

In other Lantheus news, Director James H. Thrall sold 1,000 shares of Lantheus stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the completion of the transaction, the director now directly owns 33,207 shares of the company's stock, valued at $3,146,695.32. The trade was a 2.92 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of Lantheus stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the completion of the transaction, the chief financial officer now owns 113,860 shares of the company's stock, valued at $11,445,207.20. This trade represents a 8.07 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 64,109 shares of company stock valued at $6,110,806 over the last 90 days. 2.00% of the stock is owned by insiders.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.